作者
Sankar Jagadeeshan,Manu Prasad,Mai Badarni,Talal Ben Lulu,Vijayasteltar Belsamma. Liju,Sooraj Mathukkada,Claire Saunders,Avital Beeri. Shnerb,Jonathan Zorea,Ksenia M. Yegodayev,Monica Wainer,Liza Vtorov,Irit Allon,Ofir Cohen,Gro Gausdal,Dinorah Friedmann-Morvinski,Sok Ching Cheong,Alan L. Ho,Ari Rosenberg,Linda Kessler,Francis Burrows,Dexin Kong,Jennifer R. Grandis,J. Silvio Gutkind,Moshe Elkabets
摘要
<div>Abstract<p>The survival rate for patients with head and neck cancer (HNC) diagnosed with cervical lymph node (cLN) or distant metastasis is low. Genomic alterations in the HRAS oncogene are associated with advanced tumor stage and metastasis in HNC. Elucidation of the molecular mechanisms by which mutated HRAS (HRAS<sup>mut</sup>) facilitates HNC metastasis could lead to improved treatment options for patients. Here, we examined metastasis driven by mutant HRAS <i>in vitro</i> and <i>in vivo</i> using HRAS<sup>mut</sup> human HNC cell lines, patient-derived xenografts, and a novel HRAS<sup>mut</sup> syngeneic model. Genetic and pharmacological manipulations indicated that HRAS<sup>mut</sup> was sufficient to drive invasion <i>in vitro</i> and metastasis <i>in vivo</i>. Targeted proteomic analysis showed that HRAS<sup>mut</sup> promoted AXL expression via suppressing the Hippo pathway and stabilizing YAP1 activity. Pharmacological blockade of HRAS signaling with the farnesyltransferase inhibitor tipifarnib activated the Hippo pathway and reduced the nuclear export of YAP1, thus suppressing YAP1-mediated AXL expression and metastasis. AXL was required for HRAS<sup>mut</sup> cells to migrate and invade <i>in vitro</i> and to form regional cLN and lung metastases <i>in vivo</i>. In addition, AXL-depleted HRAS<sup>mut</sup> tumors displayed reduced lymphatic and vascular angiogenesis in the primary tumor. Tipifarnib treatment also regulated AXL expression and attenuated VEGFA and VEGFC expression, thus regulating tumor-induced vascular formation and metastasis. Our results indicate that YAP1 and AXL are crucial factors for HRAS<sup>mut</sup>-induced metastasis and that tipifarnib treatment can limit the metastasis of HNC tumors with HRAS mutations by enhancing YAP1 cytoplasmic sequestration and downregulating AXL expression.</p>Significance:<p>Mutant HRAS drives metastasis of head and neck cancer by switching off the Hippo pathway to activate the YAP1–AXL axis and to stimulate lymphovascular angiogenesis.</p></div>